Publications for Wilbert S. Aronow wilbert_aronow@nymc.edu
Ahmed, M. B., Patel, K., Fonarow, G. C., Morgan, C. J., Butler, J., Bittner, V., . . . Aronow, W. S., (2016). Higher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination. ESC Heart Failure, 3(1), 11-17. doi:10.1002/ehf2.12056
Alagiakrishnan, K., Banach, M., Ahmed, A., & Aronow, W. S. (2016). Complex relationship of obesity and obesity paradox in heart failure - higher risk of developing heart failure and better outcomes in established heart failure. Annals of Medicine, 48(8), 603-613. doi:10.1080/07853890.2016.1197415
Altheeb, Z., Rana, C., Zaher, M., Doss, E., Shamoon, F., & Aronow, W. S. (2016). Amlodipine-induced ventricular tachycardia-A case report. Journal of Heart Health, 2(4) doi:10.16966/2379-769X.129
Altheeb, Z., Sbitan, A., Debari, V., Hamdan, A., Bikkina, M., Shamoon, F., . . . Aronow, W. S. (2016). Platelet reactivity unit in predicting risk of bleeding in patients undergoing coronary artery bypass graft surgery. American Journal of Therapeutics, 23(6), e1537-e1541. doi:10.1097/MJT.0000000000000208
Anand, S., Jayakumar, D., Aronow, W. S., & Chandy, D. (2016). Role of extracorporeal membrane oxygenation in adult respiratory failure: An overview. Hospital Practice, 44(2), 76-85. doi:10.1080/21548331.2016.1151325
Aronow, W. S. (2016). 2016 update on treatment of hypertension. Cardiology, 134(Suppl 1), 317.
Aronow, W. S. (2016). Current treatment of heart failure with reduction of left ventricular ejection fraction. Expert Review of Clinical Pharmacology, 9(12), 1619-1631. doi:10.1080/17512433.2016.1242067
Aronow, W. S. (2016). Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. Expert Opinion on Pharmacotherapy, 17(2), 205-215. doi:10.1517/14656566.2015.1091881
Aronow, W. S. (2016). Editor note: Early diagnosis to reduce CVD mortality. Journal of Cardiovascular Diseases & Diagnosis, 4(4), e113. doi:10.4172/2329-9517.1000e113
Aronow, W. S. (2016). Exercise rehabilitation for the treatment of intermittent claudication due to peripheral arterial disease of the lower extremities. Vascular Diseases and Therapeutics,1(1) doi:10.15761/VDT.1000101
Aronow, W. S. (2016). Fractional flow reserve. ARC Journal of Cardiology, 2(1), 7-10. doi:10.20431/2455-5991.0201005
Aronow, W. S. (2016). Iron chelation therapy for treatment of cardiac hemochromatosis. Journal of Clinical and Experimental Cardiology, 7(3), e142. doi:10.4172/2155-9880.1000e142
Aronow, W. S. (2016). Lower extremity peripheral arterial disease management. Gavin Journal of Cardiology and Cardiovascular Diseases, 2016(1), 5-11. This material can be found here.
Aronow, W. S. (2016). Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiology, 12(4), 393-396. doi:10.2217/fca-2016-0033
Aronow, W. S. (2016). Optimal blood pressure goals in patients with hypertension at high risk for cardiovascular events. American Journal of Therapeutics, 23(1), e218-e223. doi:10.1097/MJT.0b013e31827c5372
Aronow, W. S. (2016). Orthostatic hypotension in diabetics in the ACCORD (action to control cardiovascular risk in diabetes) blood pressure trial. Hypertension, 68(4), 851-852. doi:10.1161/HYPERTENSIONAHA.116.07605
Aronow, W. S. (2016). Prevention/detection/management of abdominal aortic aneurysm. AME Medical Journal, 1(4) doi:10.21037/amj.2016.12.02
Aronow, W. S. (2016). Prognosis of orthostatic hypotension. Journal of Clinical & Experimental Cardiology, 7, e147. doi:10.4172/2155-9880.1000e147
Aronow, W. S. (2016). Questions not answered by SPRINT. Journal of Hypertension Open Access, 5(1), e116. doi:10.4172/2167-1095.1000e116
Aronow, W. S. (2016). Update of treatment of heart failure with reduction of left ventricular ejection fraction. Archives of Medical Science - Atherosclerotic Diseases, 1, e106-e116. doi:10.5114/amsad.2016.63002
Aronow, W. S. (2016). What should the blood pressure treatment goal be in adults with hypertension in 2016? Annals of Translational Medicine, 4(23), 464. doi:10.21037/atm.2016.12.13
Aronow, W. S. (2016). What should the blood pressure treatment goal be in adults with hypertension in 2016? Annals of Translational Medicine, 4(23), 464. doi:10.21037/atm.2016.12.13
Aronow, W. S. (2016). What should the optimal systolic blood pressure goal be in treating older persons with hypertension? Journal of the American Medical Directors Association, 17(7), 571-573. doi:10.1016/j.jamda.2016.04.012
Aronow, W. S. (2016). What should the systolic blood pressure be in older diabetics treated for hypertension. Cardiovascular Endocrinology, 5(2), 38-39. doi:10.1097/XCE.0000000000000079
Aronow, W. S. (2016). What should the systolic blood pressure treatment goal be in patients aged 60 years and older with hypertension in 2016? Journal of Geriatric Medicine and Gerontology, 2(3), 020e. This material can be found here.
